Sanofi: Sarclisa Phase 3 Study Meets Primary Endpoint in Relapsed Multiple Myeloma
May 12 2020 - 9:19AM
Dow Jones News
By Colin Kellaher
Sanofi SA on Tuesday said a phase 3 study of Sarclisa added to
the standard-of-care treatment of carfilzomib and dexamethasone met
the primary endpoint at its first planned interim analysis in
patients with relapsed multiple myeloma.
The Paris drug maker said the addition of Sarclisa showed
significantly prolonged progression-free survival compared to
carfilzomib and dexamethasone alone in patients with the blood
cancer.
Sanofi said there were no new safety signals identified in the
study, the second positive phase 3 trial for Sarclisa, adding that
it expects the study results to form the basis of regulatory
submissions planned for later this year.
Sarclisa is approved in the U.S. in combination with
pomalidomide and dexamethasone for the treatment of adults with
relapsed refractory multiple myeloma who have received at least two
prior therapies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 12, 2020 09:04 ET (13:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
